Current landscape and challenges of neuro-oncological molecular tumor boards in Germany: results of a nationwide follow-up survey

• by Lisa S. Hönikl, Sebastian Lange, Bernhard Meyer, Stephanie E. Combs, Alisa M. Lörsch, Anna Lena Illert, Arthur Wagner, Friederike Schmidt-Graf

• March 31, 2026

Spinal ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes with a focus on the pediatric population (Part III of ependymomas across compartments)

• by Anthony M. Price, Nathan S. Fredricks, George Koutsouras, Frederic A. Vallejo, Christopher Bonfield, Devang J. Pastakia, Leo Y. Luo, Frederick Boop, Vijay Ramaswamy, Michael C. Dewan

• October 6, 2026

Malignant transformation of lower-grade glioma: contrast enhancement, extent of resection, and the natural history under interval-censored analysis

• by Baran Atli, Maximilian Wartha, Matthias Gmeiner, Martin Aichholzer, Serge Weis, Dominik Vorhauer, Helga Wagner, Tanja Hauer, Carlo Serra, Petra Böhm, Michael Sonnberger, Nico Stroh-Holly, Stefan Aspalter, Kathrin Aufschnaiter, Tobias Rossmann, Maria Gollwitzer, Jawed Ziai, Annette Leibetseder, Josef Pichler, Wolfgang Thomae, Christian Dorfer, Andreas Gruber, Harald Stefanits, Philip Rauch

• September 22, 2026

A New Era for Pancreatic Cancer: How Baptist Health Research Helped Get Us Here

Pancreatic adenocarcinoma, the most common form of pancreatic cancer, accounts for roughly 90 to 95 percent of cases. It's notoriously difficult to catch early, because symptoms often don't appear until the disease has already spread

• by

• September 24, 2026

• 11 min